Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa

BACKGROUND: We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE). METHODS: This is a real-world, multicenter, retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Alosaimy, Sara, Lagnf, Abdalhamid M, Morrisette, Taylor, Scipione, Marco R, Zhao, Jing J, Jorgensen, Sarah C J, Mynatt, Ryan, Carlson, Travis J, Jo, Jinhee, Garey, Kevin W, Allen, David, DeRonde, Kailynn, Vega, Ana D, Abbo, Lilian M, Venugopalan, Veena, Athans, Vasilios, Saw, Stephen, Claeys, Kimberly C, Miller, Mathew, Molina, Kyle C, Veve, Michael, Kufel, Wesley D, Amaya, Lee, Yost, Christine, Ortwine, Jessica, Davis, Susan L, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378588/
https://www.ncbi.nlm.nih.gov/pubmed/34430671
http://dx.doi.org/10.1093/ofid/ofab371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378588/
https://www.ncbi.nlm.nih.gov/pubmed/34430671
http://dx.doi.org/10.1093/ofid/ofab371

Ejemplares similares